MedTrace Logo

Impact of Recurrence Score on Adjuvant Treatment Decisions in Breast Cancer Patients

NCT03961880 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 270

Last updated 2025-09-16

No results posted yet for this study

Summary

IRMA is a Prospective, monocenter, non-interventional investigator initiated (IIT) registry that aims to investigate the use of the CE-marked OncotypeDX and its impact on adjuvant therapy recommendations in the clinical routine. Additionally, the proportion of patients with low, intermediate and high RS in predefined clinical subgroups will be determined. To evaluate the impact of the RS on tumor cell dissemination, these subgroups also include DTC-negative versus DTC-positive patients.

Conditions

  • Breast Cancer Female

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03961880 on ClinicalTrials.gov